Candel Therapeutics, Inc.

NASDAQ:CADL

Biotechnology

Healthcare
$5.32 +0.56%

+$0.05 today

Market cap
$417.33M
Beta
-0.48
P/E (TTM)
-9.2
EPS (TTM)
-$0.87
52W Low $4.35High $9.57

Volume 1.39M

Average 1.82M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$38.31M

FY 2025 · Annual

Investing Cash Flow

-$560,000.00

FY 2025 · Annual

Financing Cash Flow

$56.10M

FY 2025 · Annual

-40.5% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(36.12M)(18.79M)(37.94M)(55.18M)(38.18M)
Depreciation & Amortization232K778K1.28M990K845K
Deferred Income Tax11.51M0000
Stock-Based Compensation2.96M2.31M3.09M5.31M3.82M
Change in Working Capital(876K)71K(378K)346K2.19M
Accounts Receivables00000
Inventory00000
Accounts Payables669K(1.21M)45K(185K)802K
Other Working Capital(1.55M)1.28M(378K)531K1.39M
Other Non-Cash Items76K(15.78M)(301K)21.51M(6.98M)
Operating Cash Flow(22.22M)(31.42M)(34.24M)(27.02M)(38.31M)
Capital Expenditures(1.84M)(1.3M)(457K)(16K)(587K)
Acquisitions (Net)000027K
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00177K00
Investing Cash Flow(1.84M)(1.3M)(280K)(16K)(560K)
Debt Repayment019.91M0(9.17M)36.21M
Common Stock Issued71.34M00101.76M19.89M
Common Stock Repurchased00(121K)00
Dividends Paid00000
Other Financing Activities465K64K01.69M0
Financing Cash Flow71.8M19.97M(121K)94.28M56.1M
Effect of Forex Changes00000
Net Change in Cash47.75M(12.74M)(34.65M)67.24M17.23M
Free Cash Flow(24.05M)(32.72M)(34.7M)(27.04M)(38.9M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$38.2M
+ D&A$845.0K
+ Stock-Based Comp$3.8M
+ Deferred Tax$0
+ Working Capital$2.2M
- Other Non-Cash-$7.0M
= Operating Cash Flow-$38.3M
- Capex-$587.0K
= Free Cash Flow-$38.9M

Analysis

FY2025 free cash flow is -$38.9M. FCF conversion is 101.9% of net income. Operating cash flow was -$38.3M, with capex of -$587.0K. The largest bridge item is Other Non-Cash at -$7.0M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
424B5424B5 filingNov 12, 2026
10-QQuarterly reportNov 12, 2026
8-KCurrent reportNov 12, 2026
8-KCurrent reportNov 12, 2026
4Statement of changes in beneficial ownershipNov 5, 2026

Does CADL generate free cash flow?

Candel Therapeutics, Inc. (CADL) generated -$38.90M of free cash flow in fiscal 2025.

How much operating cash flow does CADL produce?

Operating cash flow was -$38.31M, before capital expenditures of $587,000.00.